세계의 콕시듐증 치료제 시장 보고서(2025년)

Coccidioidomycosis Drug Global Market Report 2025

US $ 4,490 ￦ 6,342,000

PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 6,490 ￦ 9,167,000

PDF (Site License)

PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 8,490 ￦ 11,992,000

PDF (Enterprise License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

콕시듐증 치료제 시장 규모는 향후 수년간 급성장이 전망됩니다. 2029년에는 CAGR 10.3%로 성장할 전망이며, 4억 8,000만 달러로 성장이 예측됩니다. 예측 기간의 성장은 콕시듐증 유병률 상승, 유행 지역 인구증가, 맞춤형 의료 확대, 중증 콕시듐증 사례 증가, 진균내성 관리 진보, 유행 지역 헬스케어 지출 증가, 신치요법 임상시험 진행, 충분한 치료를 받지 못한 지역에서 치료 접근성 개선, 희귀질환 관리에 대한 중점화 등에 기인한다고 볼 수 있습니다. 이 기간에 예상되는 주요 동향으로는 신약 개발을 위한 인공지능의 진보, 치료의 맞춤화를 위한 머신러닝의 이용, 표적항진균요법의 개발, 정밀의료를 위한 게놈데이터 통합, 분자바이오마커를 이용한 진단 도구 개선, 원격 환자 관리를 위한 원격 의료 성장, 나노입자를 이용한 약물 전달 혁신, 역학과 치료 성적을 위한 빅데이터 이용, 실시간 환자 모니터링 기술 진보, 가상 임상시험 플랫폼 개발 등이 있습니다.

면역 결핍 환자 증가는 향후 수년간 콕시듐증 치료제 시장의 확대를 촉진할 것으로 예측됩니다. 면역결핍자는 면역력이 저하되고 있어 인간면역결핍바이러스(HIV) 감염자, 암환자, 장기이식력이 있는 환자 등 감염증이나 질병에 걸리기 쉬워지고 있습니다. 면역결핍 집단의 증가는 만성질환 유병률 상승, 장기이식율 상승, 면역억제요법의 보급, HIV 및 AIDS 이환율 상승 등의 요인에 의해 야기되고 있습니다. 콕시듐증 치료제는 진균 감염을 제어하고 질환의 중증도를 경감하며 면역반응 저하로 생명을 위협할 수 있는 파종성 콕시듐증 등의 합병증을 예방함으로써 면역결핍 환자를 지원하는데 중요한 역할을 하고 있습니다. 예를 들면, 2024년 7월, 스위스에 본부를 두고있는 유엔 기관인 유엔 합동 HIV 및 AIDS 계획(UNAIDS)은, 2023년에는 약 3,990만 명이 HIV와 함께 생활하고 있으며 2022년의 3,900만 명으로부터 증가했다고 보고했습니다. 그 결과 면역결핍자의 증가가 콕시듐증 치료제 시장의 성장을 견인하고 있습니다.

콕시듐증 치료제 시장의 주요 기업은 선진적인 항진균 요법을 개발하고 치료 효과를 향상시키기 위해 전략적 투자를 실시했습니다. 이러한 투자를 통해 기업은 약제 내성 진균주를 표적으로 하여 환자의 전귀를 개선하는 것을 목적으로 한 신규 약제제제나 병용요법을 탐색하는 임상시험을 실시할 수 있습니다. 예를 들어 2022년 2월 미국의 공립대학인 로스앤젤레스 캘리포니아대(UCLA) 연구자들은 콕시듐증(곡열)으로 위중한 증상을 보이는 사람과 안 나오는 사람이 있는 이유를 조사하는 센터를 만들었습니다. UCLA, 샌디에이고 캘리포니아대학(UCSD), 미국 국립위생연구소(NIH)의 연구자들이 참여하는 이 공동 이니셔티브는 NIH의 보조금을 받아 자연면역반응과 적응면역반응, 콕시듐증의 게놈 기반, 진균의 병원성 인자에 초점을 맞춘 4개의 연구 프로젝트를 지원하고 있습니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향 및 전략

제4장 시장-거시경제 시나리오 금리, 인플레이션, 지정학, 신형 코로나 바이러스 감염의 영향과 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석 및 전략 분석 프레임워크

• 세계의 콕시듐증 치료제 PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인 및 억제요인)
• 최종 이용 산업의 분석
• 세계의 콕시듐증 치료제 시장 : 성장률 분석
• 세계의 콕시듐증 치료제 시장 실적 : 규모 및 성장(2019-2024년)
• 세계의 콕시듐증 치료제 시장 예측 : 규모 및 성장(2024-2029년, 2034년)
• 세계의 콕시듐증 치료제 전체 시장 규모(TAM)

제6장 시장 세분화

• 세계의 콕시듐증 치료제 시장 : 약제 유형별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
• 아졸
• 에키노캔디
• 폴리엔
• 세계의 콕시듐증 치료제 시장 : 투여 경로별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
• 오랄
• 정맥내
• 세계의 콕시듐증 치료제 시장 : 치료 단계별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
• 급성기
• 만성기
• 예방적 치료
• 세계의 콕시듐증 치료제 시장 : 환자 그룹별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
• 면역능이 있는 환자
• 면역 결핍 환자
• 세계의 콕시듐증 치료제 시장 : 최종 사용자별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
• 전문 클리닉
• 병원
• 홈케어
• 기타 최종 사용자
• 세계의 콕시듐증 치료제 시장 : 아졸 유형별 세분화 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
• 플루코나졸
• 이트라코나졸
• 보리코나졸
• 포사코나졸
• 세계의 콕시듐증 치료제 시장 : 에키노캔딘 유형별 세분화 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
• 카스포펭귄
• 미카펭귄
• 애니돌 펭귄
• 세계의 콕시듐증 치료제 시장 : 폴리엔 유형별 세분화 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
• 암호텔리신 B
• 리포좀 암포테리신 B

제7장 지역별 및 국가별 분석

• 세계의 콕시듐증 치료제 시장 : 지역별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
• 세계의 콕시듐증 치료제 시장 : 국가별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 프로파일

• 콕시듐증 치료제 시장 : 경쟁 구도
• 콕시듐증 치료제 시장 : 기업 프로파일
  • Pfizer Inc. 개요, 제품 및 서비스, 전략 및 재무 분석
  • Johnson & Johnson 개요, 제품 및 서비스, 전략 및 재무 분석
  • Merck & Co. Inc. 개요, 제품 및 서비스, 전략 및 재무 분석
  • Bayer AG 개요, 제품 및 서비스, 전략 및 재무 분석
  • Bristol Myers Squibb 개요, 제품 및 서비스, 전략 및 재무 분석

제31장 기타 주요 기업 및 혁신 기업

• Novartis AG
• Gilead Sciences Inc.
• Viatris Inc.
• Teva Pharmaceuticals USA Inc.
• Baxter International Inc.
• Astellas Pharma Inc.
• Bausch Health Companies Inc.
• Sun Pharmaceutical Industries Ltd.
• Apotex Inc.
• Cipla Limited
• Dr. Reddy's Laboratories
• Zydus Group
• Amneal Pharmaceuticals Inc.
• Recordati SpA
• Glenmark Pharmaceuticals Limited

제32장 세계 시장 경쟁 벤치마킹 및 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 부문 및 전략

• 콕시듐증 치료제 시장(2029년) : 새로운 기회를 제공하는 국가
• 콕시듐증 치료제 시장(2029년) : 새로운 기회를 제공하는 부문
• 콕시듐증 치료제 시장(2029년) : 성장 전략
  • 시장 동향에 기초한 전략
  • 경쟁 전략

제36장 부록

AJY

영문 목차

영문목차

Coccidioidomycosis drugs are medications designed to treat infections caused by *Coccidioides* species, the fungi responsible for valley fever. These drugs, including azole and polyene antifungals, help control fungal growth and alleviate symptoms. Treatment varies based on infection severity, utilizing oral, intravenous, or long-term therapy, particularly for immunocompromised patients to prevent complications.

The primary drug types in the coccidioidomycosis drug market include azoles, echinocandins, and polyenes. Azoles are a class of antifungal drugs that inhibit the synthesis of ergosterol, a crucial component of fungal cell membranes. Treatment is administered through oral or intravenous routes, with distinct phases including the acute phase, chronic phase, and prophylactic treatment. Patients are categorized into immunocompetent and immunocompromised groups, while end-users include specialty clinics, hospitals, homecare, and others.

The coccidioidomycosis drug market research report is one of a series of new reports from The Business Research Company that provides coccidioidomycosis drug market statistics, including coccidioidomycosis drug industry global market size, regional shares, competitors with a coccidioidomycosis drug market share, detailed coccidioidomycosis drug market segments, market trends and opportunities, and any further data you may need to thrive in the coccidioidomycosis drug industry. This coccidioidomycosis drug market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The coccidioidomycosis drug market size has grown strongly in recent years. It will grow from $0.33 billion in 2024 to $0.36 billion in 2025 at a compound annual growth rate (CAGR) of 8.4%. The growth during the historic period can be attributed to the rising incidence of valley fever, increasing awareness of coccidioidomycosis, advancements in antifungal medications, the expansion of healthcare infrastructure in endemic regions, increased government funding for rare disease research, the growing population of immunocompromised patients, and strengthened collaboration between pharmaceutical companies and healthcare providers.

The coccidioidomycosis drug market size is expected to see rapid growth in the next few years. It will grow to $0.48 billion in 2029 at a compound annual growth rate (CAGR) of 10.3%. The growth in the forecast period can be attributed to the rising prevalence of valley fever, a growing population in endemic regions, the expansion of personalized medicine, an increasing number of severe coccidioidomycosis cases, advancements in fungal resistance management, rising healthcare expenditure in endemic areas, ongoing clinical trials for new therapies, improved treatment access in underserved regions, and a greater focus on rare disease management. Key trends expected during this period include advancements in artificial intelligence for drug discovery, the use of machine learning for treatment personalization, the development of targeted antifungal therapies, the integration of genomic data for precision medicine, improved diagnostic tools utilizing molecular biomarkers, the growth of telemedicine for remote patient management, innovations in nanoparticle-based drug delivery, the use of big data for epidemiology and treatment outcomes, advancements in real-time patient monitoring technology, and the development of virtual clinical trial platforms.

The growing number of immunocompromised individuals is expected to drive the expansion of the coccidioidomycosis drug market in the coming years. Immunocompromised individuals have weakened immune systems, making them more vulnerable to infections and illnesses, including those with human immunodeficiency virus (HIV), cancer, or a history of organ transplants. The increase in immunocompromised populations is driven by factors such as the rising prevalence of chronic diseases, higher rates of organ transplants, widespread use of immunosuppressive therapies, and the growing incidence of HIV/AIDS. Coccidioidomycosis drugs play a critical role in helping immunocompromised patients by controlling fungal infections, reducing disease severity, and preventing complications such as disseminated coccidioidomycosis, which can be life-threatening due to weakened immune responses. For instance, in July 2024, the Joint United Nations Programme on HIV/AIDS (UNAIDS), a Switzerland-based United Nations organization, reported that approximately 39.9 million people were living with HIV in 2023, up from 39.0 million in 2022. As a result, the increasing number of immunocompromised individuals is driving the growth of the coccidioidomycosis drug market.

Leading companies in the coccidioidomycosis drug market are making strategic investments to develop advanced antifungal therapies and improve treatment effectiveness. These investments enable companies to conduct clinical trials exploring novel drug formulations and combination therapies aimed at targeting drug-resistant fungal strains and enhancing patient outcomes. For example, in February 2022, researchers at the University of California, Los Angeles (UCLA), a US-based public research university, launched a center to investigate why some individuals experience severe effects from coccidioidomycosis (valley fever) while others remain unaffected. This joint initiative, involving researchers from UCLA, the University of California, San Diego (UCSD), and the National Institutes of Health (NIH), is funded by an NIH grant and supports four research projects focusing on innate and adaptive immune responses, the genomic basis of coccidioidomycosis, and fungal virulence factors.

In November 2023, Basilea Pharmaceutica Ltd., a Switzerland-based biopharmaceutical company, acquired the rights to fosmanogepix from Amplyx Pharmaceuticals Inc. for an undisclosed amount. This acquisition positions Basilea to initiate its first phase III study with fosmanogepix in 2024, further strengthening its presence in the antifungal treatment market and addressing the urgent need for new antifungal therapies. Amplyx Pharmaceuticals Inc. is a US-based pharmaceutical company and an affiliate of Pfizer Inc., specializing in developing treatments for infectious diseases, including coccidioidomycosis.

Major players in the coccidioidomycosis drug market are Pfizer Inc., Johnson & Johnson, Merck & Co. Inc., Bayer AG, Bristol Myers Squibb, Novartis AG, Gilead Sciences Inc., Viatris Inc., Teva Pharmaceuticals USA Inc., Baxter International Inc., Astellas Pharma Inc., Bausch Health Companies Inc., Sun Pharmaceutical Industries Ltd., Apotex Inc., Cipla Limited, Dr. Reddy's Laboratories, Zydus Group, Amneal Pharmaceuticals Inc., Recordati S.p.A., Glenmark Pharmaceuticals Limited, Xellia Pharmaceuticals Pvt. Ltd., Brundavan laboratories Pvt. Ltd., LGM Pharma, Enomark Pharma.

North America was the largest region in the coccidioidomycosis drug market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in coccidioidomycosis drug report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the coccidioidomycosis drug market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The coccidioidomycosis drug market consists of revenues earned by entities by providing services such as diagnostic testing, patient management programs, pharmacovigilance services, drug consultation and advisory, clinical trials for new treatments, and education and awareness campaigns aimed at improving diagnosis, treatment adherence and overall patient outcomes. The market value includes the value of related goods sold by the service provider or included within the service offering. The coccidioidomycosis drug market also includes sales of antifungal medications and other treatment options, along with diagnostic kits, treatment formulations, intravenous therapies, and combination drug therapies designed to manage and treat valley fever and related complications. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Coccidioidomycosis Drug Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on coccidioidomycosis drug market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for coccidioidomycosis drug ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The coccidioidomycosis drug market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Drug Type: Azoles; Echinocandins; Polyenes
• 2) By Route Of Administration: Oral; Intravenous
• 3) By Treatment Phase: Acute Phase; Chronic Phase; Prophylactic Treatment
• 4) By Group Of Patients: Immunocompetent Patients; Immunocompromised Patients
• 5) By End-User: Speciality Clinics; Hospitals; Homecare; Other End-Users
• Subsegments:
• 1) By Azoles: Fluconazole; Itraconazole; Voriconazole; Posaconazole
• 2) By Echinocandins: Caspofungin; Micafungin; Anidulafungin
• 3) By Polyenes: Amphotericin B; Liposomal Amphotericin B
• Companies Mentioned: Pfizer Inc.; Johnson & Johnson; Merck & Co. Inc.; Bayer AG; Bristol Myers Squibb
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Coccidioidomycosis Drug Market Characteristics

3. Coccidioidomycosis Drug Market Trends And Strategies

4. Coccidioidomycosis Drug Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Coccidioidomycosis Drug Growth Analysis And Strategic Analysis Framework

• 5.1. Global Coccidioidomycosis Drug PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Coccidioidomycosis Drug Market Growth Rate Analysis
• 5.4. Global Coccidioidomycosis Drug Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Coccidioidomycosis Drug Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Coccidioidomycosis Drug Total Addressable Market (TAM)

6. Coccidioidomycosis Drug Market Segmentation

• 6.1. Global Coccidioidomycosis Drug Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Azoles
• Echinocandins
• Polyenes
• 6.2. Global Coccidioidomycosis Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral
• Intravenous
• 6.3. Global Coccidioidomycosis Drug Market, Segmentation By Treatment Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Acute Phase
• Chronic Phase
• Prophylactic Treatment
• 6.4. Global Coccidioidomycosis Drug Market, Segmentation By Group Of Patients, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Immunocompetent Patients
• Immunocompromised Patients
• 6.5. Global Coccidioidomycosis Drug Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Speciality Clinics
• Hospitals
• Homecare
• Other End-Users
• 6.6. Global Coccidioidomycosis Drug Market, Sub-Segmentation Of Azoles, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Fluconazole
• Itraconazole
• Voriconazole
• Posaconazole
• 6.7. Global Coccidioidomycosis Drug Market, Sub-Segmentation Of Echinocandins, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Caspofungin
• Micafungin
• Anidulfungin
• 6.8. Global Coccidioidomycosis Drug Market, Sub-Segmentation Of Polyenes, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Amphotericin B
• Liposomal Amphotericin B

7. Coccidioidomycosis Drug Market Regional And Country Analysis

• 7.1. Global Coccidioidomycosis Drug Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Coccidioidomycosis Drug Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Coccidioidomycosis Drug Market

• 8.1. Asia-Pacific Coccidioidomycosis Drug Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Coccidioidomycosis Drug Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Coccidioidomycosis Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Coccidioidomycosis Drug Market, Segmentation By Treatment Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Coccidioidomycosis Drug Market

• 9.1. China Coccidioidomycosis Drug Market Overview
• 9.2. China Coccidioidomycosis Drug Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Coccidioidomycosis Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Coccidioidomycosis Drug Market, Segmentation By Treatment Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Coccidioidomycosis Drug Market

• 10.1. India Coccidioidomycosis Drug Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Coccidioidomycosis Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Coccidioidomycosis Drug Market, Segmentation By Treatment Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Coccidioidomycosis Drug Market

• 11.1. Japan Coccidioidomycosis Drug Market Overview
• 11.2. Japan Coccidioidomycosis Drug Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Coccidioidomycosis Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Coccidioidomycosis Drug Market, Segmentation By Treatment Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Coccidioidomycosis Drug Market

• 12.1. Australia Coccidioidomycosis Drug Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Coccidioidomycosis Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Coccidioidomycosis Drug Market, Segmentation By Treatment Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Coccidioidomycosis Drug Market

• 13.1. Indonesia Coccidioidomycosis Drug Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Coccidioidomycosis Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Coccidioidomycosis Drug Market, Segmentation By Treatment Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Coccidioidomycosis Drug Market

• 14.1. South Korea Coccidioidomycosis Drug Market Overview
• 14.2. South Korea Coccidioidomycosis Drug Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Coccidioidomycosis Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Coccidioidomycosis Drug Market, Segmentation By Treatment Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Coccidioidomycosis Drug Market

• 15.1. Western Europe Coccidioidomycosis Drug Market Overview
• 15.2. Western Europe Coccidioidomycosis Drug Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Coccidioidomycosis Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Coccidioidomycosis Drug Market, Segmentation By Treatment Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Coccidioidomycosis Drug Market

• 16.1. UK Coccidioidomycosis Drug Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Coccidioidomycosis Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Coccidioidomycosis Drug Market, Segmentation By Treatment Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Coccidioidomycosis Drug Market

• 17.1. Germany Coccidioidomycosis Drug Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Coccidioidomycosis Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Coccidioidomycosis Drug Market, Segmentation By Treatment Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Coccidioidomycosis Drug Market

• 18.1. France Coccidioidomycosis Drug Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Coccidioidomycosis Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Coccidioidomycosis Drug Market, Segmentation By Treatment Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Coccidioidomycosis Drug Market

• 19.1. Italy Coccidioidomycosis Drug Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Coccidioidomycosis Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Coccidioidomycosis Drug Market, Segmentation By Treatment Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Coccidioidomycosis Drug Market

• 20.1. Spain Coccidioidomycosis Drug Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Coccidioidomycosis Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Coccidioidomycosis Drug Market, Segmentation By Treatment Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Coccidioidomycosis Drug Market

• 21.1. Eastern Europe Coccidioidomycosis Drug Market Overview
• 21.2. Eastern Europe Coccidioidomycosis Drug Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Coccidioidomycosis Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Coccidioidomycosis Drug Market, Segmentation By Treatment Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Coccidioidomycosis Drug Market

• 22.1. Russia Coccidioidomycosis Drug Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Coccidioidomycosis Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Coccidioidomycosis Drug Market, Segmentation By Treatment Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Coccidioidomycosis Drug Market

• 23.1. North America Coccidioidomycosis Drug Market Overview
• 23.2. North America Coccidioidomycosis Drug Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Coccidioidomycosis Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Coccidioidomycosis Drug Market, Segmentation By Treatment Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Coccidioidomycosis Drug Market

• 24.1. USA Coccidioidomycosis Drug Market Overview
• 24.2. USA Coccidioidomycosis Drug Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Coccidioidomycosis Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Coccidioidomycosis Drug Market, Segmentation By Treatment Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Coccidioidomycosis Drug Market

• 25.1. Canada Coccidioidomycosis Drug Market Overview
• 25.2. Canada Coccidioidomycosis Drug Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Coccidioidomycosis Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Coccidioidomycosis Drug Market, Segmentation By Treatment Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Coccidioidomycosis Drug Market

• 26.1. South America Coccidioidomycosis Drug Market Overview
• 26.2. South America Coccidioidomycosis Drug Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Coccidioidomycosis Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Coccidioidomycosis Drug Market, Segmentation By Treatment Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Coccidioidomycosis Drug Market

• 27.1. Brazil Coccidioidomycosis Drug Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Coccidioidomycosis Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Coccidioidomycosis Drug Market, Segmentation By Treatment Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Coccidioidomycosis Drug Market

• 28.1. Middle East Coccidioidomycosis Drug Market Overview
• 28.2. Middle East Coccidioidomycosis Drug Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Coccidioidomycosis Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Coccidioidomycosis Drug Market, Segmentation By Treatment Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Coccidioidomycosis Drug Market

• 29.1. Africa Coccidioidomycosis Drug Market Overview
• 29.2. Africa Coccidioidomycosis Drug Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Coccidioidomycosis Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Coccidioidomycosis Drug Market, Segmentation By Treatment Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Coccidioidomycosis Drug Market Competitive Landscape And Company Profiles

• 30.1. Coccidioidomycosis Drug Market Competitive Landscape
• 30.2. Coccidioidomycosis Drug Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Bayer AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Bristol Myers Squibb Overview, Products and Services, Strategy and Financial Analysis

31. Coccidioidomycosis Drug Market Other Major And Innovative Companies

• 31.1. Novartis AG
• 31.2. Gilead Sciences Inc.
• 31.3. Viatris Inc.
• 31.4. Teva Pharmaceuticals USA Inc.
• 31.5. Baxter International Inc.
• 31.6. Astellas Pharma Inc.
• 31.7. Bausch Health Companies Inc.
• 31.8. Sun Pharmaceutical Industries Ltd.
• 31.9. Apotex Inc.
• 31.10. Cipla Limited
• 31.11. Dr. Reddy's Laboratories
• 31.12. Zydus Group
• 31.13. Amneal Pharmaceuticals Inc.
• 31.14. Recordati S.p.A.
• 31.15. Glenmark Pharmaceuticals Limited

32. Global Coccidioidomycosis Drug Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Coccidioidomycosis Drug Market

34. Recent Developments In The Coccidioidomycosis Drug Market

35. Coccidioidomycosis Drug Market High Potential Countries, Segments and Strategies

• 35.1 Coccidioidomycosis Drug Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Coccidioidomycosis Drug Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Coccidioidomycosis Drug Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer

관련자료